Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma
NCT ID: NCT03151876
Last Updated: 2018-07-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
93 participants
INTERVENTIONAL
2017-06-12
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Busulfan are designed to kill cancer cells by binding to DNA (the genetic material of cells), which may cause cancer cells to die.
Gemcitabine and cladribine are designed to disrupt the growth of cancer cells, which may cause cancer cells to die. It may help to increase the effect of busulfan on cancer cells by not allowing these cells to repair the DNA damage caused by busulfan.
Chidamide is designed to open up the DNA and allow greater access to drugs that bind to DNA, such as cladribine, gemcitabine, busulfan.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma
NCT03602131
ChiCGB vs BEAM in High-risk or R/R Lymphomas
NCT05466318
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT03373019
Chidamide Plus R-CHOP in Elderly DLBCL
NCT02753647
Chidamide With R-CHOP Regimen for DLBCL Patients
NCT03201471
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
If you are found to be eligible to take part in this study, you will be enrolled in a group of at least 3 participants to begin receiving the study drugs.
The dose of the study drugs you receive will depend on when you enrolled in this study. If no intolerable side effects occur in your group, researchers will continue to enroll participants at the next dose level until either the vorinostat reaches the dose level currently used alone without stem cell transplant, or the highest tolerable dose of this drug is found. The dose that you receive will remain the same throughout this study.
You will be admitted to the hospital on Day -6.
Study Drug Administration (for all patients):
In stem cell transplant, the days before you receive your stem cells are called minus days. The day you receive the stem cells is called Day 0. The days after you receive your stem cells are called plus days.
On Day -7, -4, 0, +3 , you will take chidamide by mouth.
On Days -6, -5, -4, -3, and -2 you will receive cladribine by vein over 1/2 hours.
On Day -6, -2, you will receive gemcitabine by vein over 3 1/2 - 4 1/2 hours.
On Days -6, -5, -4, and -3, you will receive busulfan by vein over 3 hours.
On Day -1, you will rest.
On Day 0, you will receive your stem cells by vein over about 30-60 minutes.
As part of standard care, you will receive G-CSF (filgrastim) as an injection just under your skin twice a day starting on Day +5 until your blood cell levels return to normal.
Study Tests:
On Day -1, you will have an electrocardiogram (ECG) to check your heart function.
About 30-100 days after the transplant, you will have lung function tests.
About 100 days after the transplant:
Blood (about 4 teaspoons) will be drawn for routine tests. If the doctor thinks it is needed, you may have a bone marrow aspiration and biopsy to check the status of the disease.
You will have a PET/CT scan of your whole body to check the status of the disease.
Length of Study:
As part of standard care, you will remain in the hospital for about 3-4 weeks after the transplant. After you are released from the hospital, you will continue as an outpatient for infections and transplant-related complications.
You will be taken off study about 100 days after the transplant. You may be taken off study early if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.
This is an investigational study. Chidamide, gemcitabine, busulfan, melphalan, and rituximab are all FDA approved and commercially available. The use of these study drugs in combination is investigational.
Up to 93 patients will take part in this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ChiCGB
Experimental: ChiCGB
Chidamide administered orally on D-7, -4, 0,+3
Cladribine administered at 10mg on D-6 to D-2
Gemcitabine administered at 2500 mg/m2 on days -6 and -2.
Busulfan administered at 3.2 mg/kg (adjusted ideal body weight) on days -6 to -3.
Dexamethasone 10 mg by vein daily from day -6 to day -1. Caphosol oral rinses 30 mL four times a day used from day -8.
Interventions:
Drug: Chidamide Drug: Cladribine Drug: Gemcitabine Drug: Busulfan Drug: Dexamethasone Procedure: Stem Cell Transplant
Chidamide
30 mg oral twice weekly for 2 weeks
Cladribine
6 mg/m2 intravenously daily for 5 days
gemcitabine
2500 mg/m2 intravenously twice weekly for 1 week
Busulfan
3.2 mg/kg intravenously daily for 4 days
Autologous hematopoietic stem cell transplantation
autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chidamide
30 mg oral twice weekly for 2 weeks
Cladribine
6 mg/m2 intravenously daily for 5 days
gemcitabine
2500 mg/m2 intravenously twice weekly for 1 week
Busulfan
3.2 mg/kg intravenously daily for 4 days
Autologous hematopoietic stem cell transplantation
autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Relapsed patients should respond to 2nd or 3rd line salvage chemotherapy and attain at least PR before recruitment.
3. Adequate renal function, as defined by estimated serum creatinine clearance \>/=50 ml/min and/or serum creatinine \</= 1.8 mg/dL.
6\. Adequate hepatic function, as defined by serum glutamate oxaloacetate transaminase (SGOT) and/or serum glutamate pyruvate transaminase (SGPT) \</= 3 x upper limit of normal; serum bilirubin and alkaline phosphatase \</= 2 x upper limit of normal.
7\. Adequate pulmonary function with forced expiratory volume at one second (FEV1), forced vital capacity (FVC) and diffusing capacity of lung for carbon monoxide (DLCO) \>/= 50% of expected corrected for hemoglobin.
8\. Adequate cardiac function with left ventricular ejection fraction \>/= 50%. No uncontrolled arrhythmias or symptomatic cardiac disease.
9\. Performance status 0-1. 10. Negative Beta diffusing capacity of lung for carbon monoxide (HCG) text in a woman with child-bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization
Exclusion Criteria
2. Patients relapsed after ASCT
3. Bone marrow was involved by lymphoma
4. Patients with active hepatitis B or C(HBV DNA \>/=10,000 copies/mL).
5. Active infection requiring parenteral antibiotics
6. HIV infection, unless the patient is receiving effective antiretroviral therapy with undetectable viral load and normal cluster of differentiation 4 (CD4) counts
7. Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology.
8. Patients with a cQT longer than 500 ms
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sichuan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jie Ji
Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ting Liu, MD
Role: PRINCIPAL_INVESTIGATOR
West China Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing cancer hospital
Beijing, Beijing Municipality, China
Peking university third hospital
Beijing, Beijing Municipality, China
The first affiliated hospital of Chongqing medical university
Chongqing, Chongqing Municipality, China
Southwest Hospital
Chongqing, Chongqing Municipality, China
General Hospital of Lanzhou military command
Lanzhou, Gansu, China
Henan cancer hospital
Zhengzhou, Henan, China
The first affiliated hospital of Zhengzhou university
Zhengzhou, Henan, China
Tongji Hospital
Wuhan, Hubei, China
Jiangsu province hospital
Nanjing, Jiangsu, China
Rui jin hospital Shanghai jiao tong University
Shanghai, Shanghai Municipality, China
Tong Ren Hospital
Shanghai, Shanghai Municipality, China
Shan Xi Da Yi Hospital
Taiyuan, Shanxi, China
Tangdu Hospital
Xi’an, Shanxi, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Affiliated Hospital of Southwest Medical University
Nanchong, Sichuan, China
Blood diseases hospital, Chinese academy of medica
Tianjin, Tianjing, China
The first affiliated hospital of Xinjiang medical Universtiy
Ürümqi, Xinjiang, China
Kunming General Hospital of Chengdu Military Area
Kunming, Yunnan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yan Xie, MD
Role: primary
Xiaoyan Ke, MD
Role: primary
Lin Liu, MD
Role: primary
Dabing Qin, MD
Role: primary
Hai Bai, MD
Role: primary
Jian Zhou, MD
Role: primary
Xinhua Wang, MD
Role: primary
Yang Cao, MD
Role: primary
Wei Xu, MD
Role: primary
Jiong Hu, MD
Role: primary
Ligen L i u, MD
Role: primary
Rong Gong, MD
Role: primary
Qiang Liu, MD
Role: primary
Xiaoming Li, MD
Role: primary
Lvgui Qiu, MD
Role: primary
Ming Jiang, MD
Role: primary
Sanbin Wang, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Ji J, Liu Z, Kuang P, Dong T, Chen X, Li J, Zhang C, Liu J, Zhang L, Shen K, Liu T. A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas. Int J Cancer. 2021 Dec 15;149(12):2075-2082. doi: 10.1002/ijc.33761. Epub 2021 Aug 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ChiCGB-DLBCL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.